These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 24084047)

  • 1. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
    Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
    Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.
    Tai S; Fantegrossi WE
    Curr Top Behav Neurosci; 2017; 32():249-262. PubMed ID: 28012093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
    Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
    Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
    Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
    Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
    Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
    Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
    Brents LK; Reichard EE; Zimmerman SM; Moran JH; Fantegrossi WE; Prather PL
    PLoS One; 2011; 6(7):e21917. PubMed ID: 21755008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Cannabinoids.
    Mills B; Yepes A; Nugent K
    Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?
    Seely KA; Prather PL; James LP; Moran JH
    Mol Interv; 2011 Feb; 11(1):36-51. PubMed ID: 21441120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Pot: Not Your Grandfather's Marijuana.
    Ford BM; Tai S; Fantegrossi WE; Prather PL
    Trends Pharmacol Sci; 2017 Mar; 38(3):257-276. PubMed ID: 28162792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
    Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
    Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018.
    Su MK; Seely KA; Moran JH; Hoffman RS
    Clin Pharmacol Ther; 2015 Jun; 97(6):562-4. PubMed ID: 25788107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.
    Tai S; Fantegrossi WE
    Curr Addict Rep; 2014 Jun; 1(2):129-136. PubMed ID: 26413452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
    Brents LK; Gallus-Zawada A; Radominska-Pandya A; Vasiljevik T; Prisinzano TE; Fantegrossi WE; Moran JH; Prather PL
    Biochem Pharmacol; 2012 Apr; 83(7):952-61. PubMed ID: 22266354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.
    Järbe TU; Gifford RS
    Life Sci; 2014 Feb; 97(1):64-71. PubMed ID: 23891559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Δ
    Breivogel CS; Brenseke BM; Eldeeb K; Nichols K; Jonas A; Mistry AH; Barbalato L; Luibil N; Howlett AC; Leone-Kabler S; Hilgers RPH; Pulgar VM
    Cannabis Cannabinoid Res; 2024 Aug; 9(4):e1056-e1062. PubMed ID: 37010379
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential Mechanisms Underlying the Deleterious Effects of Synthetic Cannabinoids Found in Spice/K2 Products.
    Basavarajappa BS; Subbanna S
    Brain Sci; 2019 Jan; 9(1):. PubMed ID: 30654473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.
    Thomas BF; Lefever TW; Cortes RA; Grabenauer M; Kovach AL; Cox AO; Patel PR; Pollard GT; Marusich JA; Kevin RC; Gamage TF; Wiley JL
    J Pharmacol Exp Ther; 2017 Apr; 361(1):162-171. PubMed ID: 28087785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
    Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
    Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.